Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KYTX

Kyverna Therapeutics Inc.

May 10 • 04:00PM ET

14.00

Dollar change -0.60
Percentage change -4.11	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF SCHA VTI ITOT SCHB IBRN BMED

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	29.61%	Shs Outstand	43.12M	Perf Week	-8.20%
Market Cap	603.68M	Forward P/E	-	EPS next Y	-4.00	Insider Trans	19.27%	Shs Float	30.35M	Perf Month	-41.40%
Income	-	PEG	-	EPS next Q	-0.84	Inst Own	6.71%	Short Float	6.40%	Perf Quarter	-53.49%
Sales	-	P/S	-	EPS this Y	96.35%	Inst Trans	-	Short Ratio	4.85	Perf Half Y	-
Book/sh	-3.05	P/B	-	EPS next Y	-22.14%	ROA	-	Short Interest	1.94M	Perf Year	-
Cash/sh	1.33	P/C	10.49	EPS next 5Y	-	ROE	-	52W Range	12.26 - 35.06	Perf YTD	-53.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-60.07%	Beta	-
Dividend TTM	-	Quick Ratio	3.05	Sales past 5Y	-37.90%	Gross Margin	-	52W Low	14.19%	ATR (14)	1.57
Dividend Ex-Date	-	Current Ratio	3.05	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	33.77	Volatility	11.96% 9.84%
Employees	96	Debt/Eq	0.18	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	42.75
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	-	Payout	-	Rel Volume	0.54	Prev Close	14.60
Sales Surprise	-	EPS Surprise	-2819.81%	Sales Q/Q	-	Earnings	Mar 26 AMC	Avg Volume	399.96K	Price	14.00
SMA20	-18.95%	SMA50	-37.89%	SMA200	-41.45%	Trades		Volume	217,579	Change	-4.11%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-24	Initiated	Wells Fargo	Overweight	$44
Mar-04-24	Initiated	Morgan Stanley	Overweight	$40
Mar-04-24	Initiated	Leerink Partners	Outperform	$48
Mar-04-24	Initiated	JP Morgan	Overweight	$39

Apr-11-24 05:01PM	Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Mar-29-24 02:59PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
Mar-14-24 07:00AM	Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Mar-07-24 07:26PM	Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis (PR Newswire)
06:14PM	Loading…
06:14PM	How Kyverna is positioned for success on autoimmune therapy: CEO (Yahoo Finance Video)
Feb-12-24 04:39PM	Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-07-24 10:29PM	Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119	Feb 13 05:48 PM
Northpond Ventures III GP, LLC	Former 10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	450,000	Feb 12 05:51 PM
Bain Capital Life Sciences Inv	10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	3,163,868	Feb 14 05:26 PM
Vida Ventures, LLC	10% Owner	Feb 12 '24	Buy	22.00	253,136	5,568,992	252,553	Feb 14 07:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KYTX

Kyverna Therapeutics Inc.

Upgrade your FINVIZ experience